Eli Lilly’s $3.25B acquisition of Kelonia Therapeutics caps startup’s tortuous ride
statnews.com • • general
Key Points:
- Eli Lilly is acquiring Kelonia Therapeutics for $3.25 billion, with potential additional payments tied to clinical, regulatory, and commercial milestones.
- Kelonia is developing cell therapies targeting cancer and autoimmune diseases, representing a strategic expansion for Lilly in these areas.
- The acquisition provides significant support to Kelonia, a small biotech that has operated on just $60 million over five years and faced multiple near-cash-out situations.
- Bryan Roberts of Venrock, which incubated Kelonia, shared early investment documents revealing insights into the challenges of launching a biotech startup amid intense competition in gene therapy.
